Genmab Resultados de beneficios anteriores

Pasado controles de criterios 2/6

Genmab ha aumentado sus ingresos a un ritmo medio anual de 17.7%, mientras que la industria Biotechs ha visto aumentar sus ingresos growing a 17.7% anualmente. Los ingresos han crecido growing a un ritmo medio anual de 28.4%. Genmab La rentabilidad de los fondos propios de la empresa es de 13.8% y sus márgenes netos son de 26.4%.

Información clave

17.7%

Tasa de crecimiento de los beneficios

17.0%

Tasa de crecimiento del BPA

Crecimiento de la industria Biotechs	18.7%
Tasa de crecimiento de los ingresos	28.4%
Rentabilidad financiera	13.8%
Margen neto	26.4%
Próxima actualización de resultados	02 May 2024

Actualizaciones de resultados anteriores recientes

Genmab's (CPH:GMAB) Conservative Accounting Might Explain Soft Earnings

Feb 21

Recent updates

Genmab A/S' (CPH:GMAB) Price In Tune With Earnings

Apr 02

We Think Genmab A/S' (CPH:GMAB) CEO Compensation Package Needs To Be Put Under A Microscope

Mar 07

Desglose de ingresos y gastos
Beta

Cómo gana y gasta dinero Genmab. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).

Historial de beneficios e ingresos

CPSE:GMAB Ingresos, gastos y beneficios (DKK Millions)
Fecha	Ingresos	Beneficios	Gastos G+A	Gastos de I+D
31 Dec 23	16,474	4,352	3,297	7,630
30 Sep 23	17,023	4,296	3,284	7,285
30 Jun 23	16,366	4,749	3,115	6,683
31 Mar 23	15,330	5,283	2,900	6,112
31 Dec 22	14,505	5,452	2,676	5,524
30 Sep 22	11,987	5,654	2,267	5,219
30 Jun 22	10,210	3,962	1,903	4,847
31 Mar 22	9,020	2,377	1,534	4,486
31 Dec 21	8,417	2,957	1,283	4,181
30 Sep 21	7,907	2,873	1,002	3,787
30 Jun 21	7,321	2,513	841	3,394
31 Mar 21	10,800	5,585	756	3,248
31 Dec 20	10,111	4,758	661	3,137
30 Sep 20	11,028	5,649	546	2,880
30 Jun 20	10,344	5,656	483	2,766
31 Mar 20	5,667	2,363	377	2,555
31 Dec 19	5,366	2,166	342	2,386
30 Sep 19	3,641	1,528	285	2,173
30 Jun 19	3,199	1,170	258	1,910
31 Mar 19	2,935	1,345	241	1,664
31 Dec 18	3,025	1,472	214	1,431
30 Sep 18	2,807	1,424	195	1,227
30 Jun 18	2,532	1,239	177	1,112
31 Mar 18	2,796	1,286	157	995
31 Dec 17	2,365	1,104	147	852
30 Sep 17	2,275	1,159	131	795
30 Jun 17	2,316	1,354	121	718
31 Mar 17	1,897	1,215	110	704
31 Dec 16	1,816	1,187	102	661
30 Sep 16	1,463	735	101	642
30 Jun 16	1,376	686	94	606
31 Mar 16	1,196	535	93	529
31 Dec 15	1,133	764	91	488
30 Sep 15	774	443	92	443
30 Jun 15	768	463	90	441
31 Mar 15	710	420	86	459
31 Dec 14	850	301	80	506
30 Sep 14	851	292	77	517
30 Jun 14	729	138	72	534
31 Mar 14	751	138	69	545
31 Dec 13	664	70	67	528
30 Sep 13	611	-5	64	539
30 Jun 13	577	-55	65	535

Ingresos de calidad: GMAB tiene ganancias de alta calidad.

Margen de beneficios creciente: GMABLos actuales márgenes de beneficio netos de (26.4%) son inferiores a los del año pasado (37.6%).

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: GMABLos beneficios de la empresa han crecido un 17.7% al año en los últimos 5 años.

Acelerando crecimiento: GMAB's ha tenido un crecimiento negativo de los beneficios en el último año, por lo que no puede compararse con su media de 5 años.

Beneficios vs. Industria: GMAB tuvo un crecimiento negativo de los beneficios (-20.2%) durante el año pasado, lo que dificulta la comparación con la media del sector Biotechs (-20.2%).

Rentabilidad financiera

Alto ROE: El Retorno sobre el capital de GMAB (13.8%) se considera bajo.

Rentabilidad económica

Rendimiento del capital invertido

Descubre empresas con buenos resultados en el pasado

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Genmab Resultados de beneficios anteriores

Pasado controles de criterios 2/6

Información clave

Actualizaciones de resultados anteriores recientes

Genmab's (CPH:GMAB) Conservative Accounting Might Explain Soft Earnings

Full year 2023 earnings: EPS misses analyst expectations

Third quarter 2023 earnings released: EPS: kr.32.60 (vs kr.39.55 in 3Q 2022)

Genmab A/S to Report Q1, 2024 Results on May 02, 2024

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

First quarter 2023 earnings released: EPS: kr.3.46 (vs kr.7.10 in 1Q 2022)

Recent updates

Genmab A/S (CPSE:GMAB) entered into a definitive agreement to acquire ProfoundBio for $1.8 billion.

Genmab A/S (CPSE:GMAB) entered into a definitive agreement to acquire ProfoundBio for $1.8 billion.

Genmab A/S' (CPH:GMAB) Price In Tune With Earnings

Genmab A/S Announces Executive Changes

We Think Genmab A/S' (CPH:GMAB) CEO Compensation Package Needs To Be Put Under A Microscope

Executive VP & CFO recently sold kr.22m worth of stock

Executive VP & CFO exercised options to buy kr.22m worth of stock.

Genmab A/S and AbbVie Announce U.S. Food and Drug Administration Grants Priority Review for the Supplemental Biologics License Application for Epcoritamab (Epkinly®) for Difficult-To-Treat Relapsed or Refractory Follicular Lymphoma

Genmab's (CPH:GMAB) Conservative Accounting Might Explain Soft Earnings

Full year 2023 earnings: EPS misses analyst expectations

Genmab A/S and Pfizer, Inc. Announces Validation for Review the Marketing Authorization Application of Tivdak®?

Genmab A/S Announces Decision in Arbitration Appeal Under License Agreement with Janssen Biotech, Inc

Pfizer Inc. and Genmab A/S Announce U.S. Food and Drug Administration Accepts TIVDAK® Supplemental Biologics License Application

Genmab A/S and AbbVie Announces New Pivotal Data for Bispecific Antibody Epcoritamab (Duobody CD3xCD20) Demonstrates High Overall and Complete Responses in Patients with Hard-To-Treat Relapsed/Refractory Follicular Lymphoma

Genmab A/S Announces Positive Regulatory Updates for Epcoritamab (EPKINLY®?/TEPKINLY®?) for the Treatment of Relapsed/Refractory Follicular Lymphoma

Genmab A/S Announces Positive Regulatory Updates for Epcoritamab (EPKINLY®?/TEPKINLY®?) for the Treatment of Relapsed/Refractory Follicular Lymphoma

Is Genmab A/S (CPH:GMAB) Trading At A 50% Discount?

Genmab A/S Revises Earnings Guidance for the Year 2023

Third quarter 2023 earnings released: EPS: kr.32.60 (vs kr.39.55 in 3Q 2022)

Genmab A/S, Annual General Meeting, Mar 13, 2024

Genmab A/S to Report Q1, 2024 Results on May 02, 2024

Genmab A/S and Seagen Inc. Announce Additional Results from the Phase 3 innovaTV 301 Randomized Global Trial

Investor sentiment deteriorates as stock falls 16%

Genmab A/S Announces European Commission Approval of Tepkinly(R) (epcoritamab) for Adults with Relapsed Or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Seagen Inc. and Genmab A/S Announce That Tivdak(R) (Tisotumab Vedotin-Tftv) Met Its Primary Endpoint of Improved Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared to Chemotherapy

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Genmab A/S Revises Earning Guidance for the Year 2023

Genmab A/S Announces AbbVie Receives Positive CHMP Opinion for Epcoritamab (TEPKINLY(R) Diffuse Large B-Cell Lymphoma

AbbVie and Genmab Announce Positive Topline Results from Phase 1/2 EPCORE™ NHL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Follicular Lymphoma (FL)

Genmab A/S Announces Epcoritamab Added to National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology for ‘B-Cell Lymphomas’

Is Now The Time To Put Genmab (CPH:GMAB) On Your Watchlist?

Genmab A/S Showcases Data from Comprehensive Epcoritamab Development Program in Patients Across B-Cell Lymphomas At European Hematology Association (EHA) Annual Meeting 2023

Co-Founder recently sold kr.58m worth of stock

Is There An Opportunity With Genmab A/S' (CPH:GMAB) 44% Undervaluation?

U.S. Food and Drug Administration Approves Genmab A/S’s EPKINLY (epcoritamab-bysp) as the First and Only Bispecific Antibody to Treat Adults with Relapsed or Refractory Diffuse Large B-cell Lymphoma

Genmab A/S Provides Earnings Guidance for 2023

First quarter 2023 earnings released: EPS: kr.3.46 (vs kr.7.10 in 1Q 2022)

Independent Chairman of the Board recently bought kr.796k worth of stock

With EPS Growth And More, Genmab (CPH:GMAB) Makes An Interesting Case

Genmab A/S (CPH:GMAB) Shares Could Be 50% Below Their Intrinsic Value Estimate

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Insufficient new directors

Genmab A/S Announces Submission of Japan New Drug Application for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma

Here's Why We Think Genmab (CPH:GMAB) Is Well Worth Watching

Co-Founder recently sold kr.57m worth of stock

Genmab A/S Showcases Data From Robust Development Program Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients Across a Broad Range of B-Cell Lymphomas at the 64th Annual ASH Meeting

Genmab A/S to Report Nine Months, 2023 Results on Nov 07, 2023

Are Investors Undervaluing Genmab A/S (CPH:GMAB) By 46%?

Genmab A/S Announces U.S. Food and Drug Administration Accepts for Priority Review Biologics License Application (Bla) for Epcoritamab (Duobody®-Cd3xcd20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (Lbcl)

Consensus EPS estimates increase by 45%

Third quarter 2022 earnings released: EPS: kr.39.55 (vs kr.13.61 in 3Q 2021)

Genmab Provides Earnings Guidance for Year 2022

Genmab A/S Submits Biologics License Application to the U.S. Food and Drug Administration

Do Genmab's (CPH:GMAB) Earnings Warrant Your Attention?

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Genmab A/S Revises Earnings Guidance for the Year 2022

Genmab A/S Submits Biologics License Application to U.S. Food and Drug Administration for Epcoritamab for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma

Investor sentiment improved over the past week

Genmab Announces Late-Breaking Phase 2 Trial Results of Investigational Epcoritamab (DuoBody®-CD3xCD20) in Relapsed/Refractory Large B-cell Lymphoma (LBCL) Patients Presented at European Hematology Association (EHA) Presidential Symposium

Genmab A/S and Seagen Inc. Present Data from Tisotumab Vedotin (TIVDAK) Clinical Development Program and Additional Cervical Cancer Research at ASCO 2022 Annual Meeting

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Genmab A/S Revises Earnings Guidance for 2022

AbbVie and Genmab Announce Topline Results for Epcoritamab (DuoBody®-CD3xCD20) from Phase 1/2 Trial in Patients with Relapsed/Refractory Large B-cell Lymphoma (LBCL)

Genmab A/S Elects Elizabeth O’Farrell to the Board of Directors

Genmab A/S Announces Appointments of Birgitte Stephensen to Chief Legal Officer and Chris Cozic to Chief People Officer

Desglose de ingresos y gastosBeta

Historial de beneficios e ingresos

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Desglose de ingresos y gastos
Beta